UNBS5162 and amonafide inhibits tumor progression in human melanoma by the AKT/mTOR pathway

References

• LensMBDawesMGlobal perspectives of contemporary epidemiological trends of cutaneous malignant melanomaBr J Dermatol2004150217918514996086
   PubMed Web of Science ®Google Scholar
• MichielinOHoellerCGaining momentum: new options and opportunities for the treatment of advanced melanomaCanc Treat Rev2015418660670
   PubMed Web of Science ®Google Scholar
• GarbeCEigentlerTKKeilholzUHauschildAKirkwoodJMSystematic review of medical treatment in melanoma: current status and future prospectsOncologist201116152421212434
   PubMed Web of Science ®Google Scholar
• SeregardSSinghADRetinoblastoma: direct chemotherapeutic drug delivery into the vitreous cavityBr J Ophthalmol201296447347422421997
   PubMed Web of Science ®Google Scholar
• KumariGSinghRKGreen synthesis, antibacterial activity, and SAR of some novel naphthalimides and allylidenesMed Chem Res2015241171181
   Web of Science ®Google Scholar
• MijatovicTMahieuTBruyèreCUNBS5162, a novel naphthalimide that decreases CXCL chemokine expression in experimental prostate cancersNeoplasia200810657358618516294
   PubMed Web of Science ®Google Scholar
• BruyèreCMijatovicTDenèveN47 poster UNBS5162: a new naphthalimide derivative with radiosensitizing and anti-angiogenic activity entering phase IEJC Suppl2008618
   Google Scholar
• CostanzaMEBerryDHendersonICAmonafide: an active agent in the treatment of previously untreated advanced breast cancer—a cancer and leukemia group B study (CALGB 8642)Clin Canc Res199517699704
   PubMed Web of Science ®Google Scholar
• WangBShenJWangJUNBS5162 inhibits proliferation of human retinoblastoma cells by promoting cell apoptosisOnco Targets Ther2017105303530929158682
   PubMed Web of Science ®Google Scholar
• KornekGRadererMDepischDAmonafide as first-line chemotherapy for metastatic breast cancerEur J Canc1994303398400
   Google Scholar
• JazirehiARWennPBDamavandMTherapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapyAm J Canc Res201222178191
   PubMed Web of Science ®Google Scholar
• WuXYuJYanJPI3K/Akt/mTOR pathway inhibitors inhibit the growth of melanoma cells with mTOR H2189Y mutations in vitroCanc Biol Ther2018197584589
   PubMed Web of Science ®Google Scholar
• ZattaKFrankLReolonLAn inhalable powder formulation based on micro- and nanoparticles containing 5-fluorouracil for the treatment of metastatic melanomaNanomaterials20188275
   Web of Science ®Google Scholar
• LiXLinYWangQYuanYZhangHQianXThe novel anti-tumor agents of 4-triazol-1,8-naphthalimides: synthesis, cytotoxicity, DNA inter-calation and photocleavageEur J Med Chem20114641274127921345546
   PubMed Web of Science ®Google Scholar
• CholodyWKosalowska-CholodyTMichejdaCinventorsHEALTH AND HUMAN SERVICES GOVERNMENT OF United States, DEARTMENT OF, Secretary of, assignee1,8-naphthalimide imidazo{4,5,1-de}acridones with anti-tumor activityUnited States patent US20030203916A1200381
   Google Scholar
• JiLYangSLiSA novel triazolonaphthalimide induces apoptosis and inhibits tumor growth by targeting DNA and DNA-associated processesOncotarget2017823373943740828445124
   PubMedGoogle Scholar
• BrañaMFCastellanoJMRoldánCMSantosAVázquezDJiménezASynthesis and mode(s) of action of a new series of imide derivatives of 3-nitro-1,8 naphthalic acidCanc Chemother Pharmacol1980416166
   PubMed Web of Science ®Google Scholar
• MahadevanDNorthfeltDWChalasaniPPhase I trial of UNBS5162, a novel naphthalimide in patients with advanced solid tumors or lymphomaInt J Clin Oncol201318593494123053399
   PubMed Web of Science ®Google Scholar
• AllenSLKolitzJELundbergAPhase I study of amonafide + cytosine arabinoside (araC) in patients with poor risk acute myeloid leukemia (AML)J Clin Oncol20052316_suppl6602
   Web of Science ®Google Scholar
• MahieuTMijatovicTDumontPUNBS5162: a novel naphthalimide derivative with potent pro-autophagic effects in human cancer cellsCanc Res2007674831
   Google Scholar
• GellermanGRecent developments in the synthesis and applications of anticancer amonafide derivatives. A mini reviewLet Drug Des Discov2016131
   PubMed Web of Science ®Google Scholar
• LiraSAFurtadoGCThe biology of chemokines and their receptorsAnnu Rev Immunol201254111120
   Google Scholar
• ViolaALusterADChemokines and their receptors: drug targets in immunity and inflammationAnnu Rev Pharmacol Toxicol200848117119717883327
   PubMedGoogle Scholar
• AkramIGGeorgesRHielscherTAdwanHBergerMRThe chemokines CCR1 and CCRL2 have a role in colorectal cancer liver metastasisTumour Biol20163722461247126383527
   PubMedGoogle Scholar
• VerbekeHGeboesKvanDJStruyfSThe role of CXC chemokines in the transition of chronic inflammation to esophageal and gastric cancerBiochim Biophys Acta: Rev Canc18252012117129
   Google Scholar
• SchraderAJLechnerOTemplinMCXCR4/CXCL12 expression and signalling in kidney cancerBr J Canc200286812501256
   PubMed Web of Science ®Google Scholar
• JordanJTSunWHussainSFDeanguloGPrabhuSSHeimbergerABPreferential migration of regulatory T cells mediated by gliomasecreted chemokines can be blocked with chemotherapyCanc Immunol Immunother2008571123131
   PubMed Web of Science ®Google Scholar
• ChengZHShiYXYuanMXiongDZhengJHZhangZYChemokines and their receptors in lung cancer progression and metastasisJ Zhejiang Univ Sci B201617534235127143261
   PubMed Web of Science ®Google Scholar
• NagarshethNPengDKryczekIPRC2 epigenetically silences Th1-type chemokines to suppress effector T-cell trafficking in colon cancerCanc Res2016762275282
   PubMed Web of Science ®Google Scholar
• SoriaGBen-BaruchAThe inflammatory chemokines CCL2 and CCL5 in breast cancerCanc Lett20082672271285
   PubMed Web of Science ®Google Scholar
• KobayashiHNobeyamaYNakagawaHTumor-suppressive effects of natural-type interferon-β through CXCL10 in melanomaBiochem Biophys Res Commun2015464241642126102027
   PubMed Web of Science ®Google Scholar
• DhawanPRichmondARole of CXCL1 in tumorigenesis of melanomaJ Leukoc Biol2002721912101257
   PubMed Web of Science ®Google Scholar
• O’BoyleGSwidenbankIMarshallHInhibition of CXCR4-CXCL12 chemotaxis in melanoma by AMD11070Br J Canc2013108816341640
   PubMed Web of Science ®Google Scholar
• WuSSinghSVarneyMLKindleSSinghRKModulation of CXCL-8 expression in human melanoma cells regulates tumor growth, angiogenesis, invasion, and metastasisCanc Med201213306317
   PubMed Web of Science ®Google Scholar
• SinghSSAVarneyMLNannuruKCSinghRKCXCR1, CXCR2, melanoma, CXCL-8Int J Canc J Int Du Canc2010126328
   PubMedGoogle Scholar
• D’ArcangeloDFacchianoFNassaGPDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approachOncotarget20167477725727764787
   PubMedGoogle Scholar
• MijatovicTMahieuTBruyèreCUNBS5162, CXCL, prostate cancerNeoplasia20081057358618516294
   PubMed Web of Science ®Google Scholar
• StoneRMMazzolaENeubergDPhase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemiaJ Clin Oncol201533111252125725732165
   PubMed Web of Science ®Google Scholar